Bavarian Nordic A/S (CPH:BAVA)
Denmark · Delayed Price · Currency is DKK 183.30
-2.95 (-1.58%)
At close: Mar 19, 2026
Bavarian Nordic Revenue
In the year 2025, Bavarian Nordic had annual revenue of 6.24B DKK with 9.23% growth. Bavarian Nordic had revenue of 1.45B in the quarter ending December 31, 2025, a decrease of -30.70%.
Revenue
6.24B
Revenue Growth
+9.23%
P/S Ratio
2.31
Revenue / Employee
3.69M
Employees
1,692
Market Cap
14.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.24B | 527.75M | 9.23% |
| Dec 31, 2024 | 5.72B | -1.35B | -19.06% |
| Dec 31, 2023 | 7.06B | 3.91B | 124.14% |
| Dec 31, 2022 | 3.15B | 1.25B | 66.02% |
| Dec 31, 2021 | 1.90B | 45.49M | 2.46% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk | 309.06B |
| Coloplast | 27.89B |
| H. Lundbeck | 24.63B |
| Genmab | 23.66B |
| GN Store Nord | 16.78B |
| Zealand Pharma | 9.21B |
| ALK-Abelló | 6.31B |
| Ambu A/S | 6.09B |
Bavarian Nordic News
- 2 days ago - Mpox Is on the Rise. 3 Vaccine Stocks Worth a Second Look. - Barrons
- 3 days ago - Bavarian Nordic – Transactions in Connection with Share Buy-Back Program - GlobeNewsWire
- 7 days ago - Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such - GlobeNewsWire
- 7 days ago - Bavarian Nordic AS (BVNKF) Q4 2025 Earnings Call Highlights: Strong Financial Performance and ... - GuruFocus
- 7 days ago - Bavarian Nordic Launches Next Tranche of Share Buy-Back Program - GlobeNewsWire
- 7 days ago - Bavarian Nordic Publishes Annual Report 2025 - GlobeNewsWire
- 8 days ago - Bavarian Nordic and Serum Institute of India Expand Strategic Partnership with Chikungunya Vaccine Manufacturing Agreement - GlobeNewsWire
- 4 weeks ago - Bavarian Nordic Receives USD 22.5 Million Contract for its Mpox and Smallpox Vaccine from the Government of Canada - GlobeNewsWire